Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.